AU Patent

AU2013202235B2 — Use of Hsp70 as a regulator of enzymatic activity

Assigned to Zevra Denmark AS · Expires 2015-04-23 · 11y expired

What this patent protects

Abstract The present invention concerns a method for modulating the enzymatic activity of an enzyme, wherein said enzyme interacts with BMP, said method comprising the step of administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for all…

USPTO Abstract

Abstract The present invention concerns a method for modulating the enzymatic activity of an enzyme, wherein said enzyme interacts with BMP, said method comprising the step of administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for allowing interaction between BMP and Hsp70, or said functional fragment or variant thereof, and thereby modulating the enzymatic activity of an enzyme interacting with BMP.

Drugs covered by this patent

Patent Metadata

Patent number
AU2013202235B2
Jurisdiction
AU
Classification
—
Expires
2015-04-23
Drug substance claim
No
Drug product claim
No
Assignee
Zevra Denmark AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.